Core Viewpoint - MBX Biosciences, Inc. has appointed Karen Basbaum as Chief Business Officer, bringing over 20 years of experience in corporate strategy and business development within the biotechnology and pharmaceutical sectors [1][3]. Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders [1][5]. - The company utilizes its proprietary PEP™ platform to advance a pipeline of candidates targeting significant unmet medical needs [5]. Leadership Appointment - Karen Basbaum's extensive background includes leading strategic partnerships and corporate transactions valued at over $10 billion during her tenure at Poseida Therapeutics [3][4]. - Her previous roles include senior positions at DNAtrix, Dauntless Pharmaceuticals, and Elcelyx Therapeutics, contributing to major corporate transactions, including a $7 billion acquisition by Bristol Myers Squibb [4]. Pipeline Development - MBX's pipeline includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development, and an obesity portfolio with candidates in various stages of development [5]. - The company is also advancing imapextide (MBX 1416) for post-bariatric hypoglycemia, currently in Phase 2 development [5].

Core Insights - MBX Biosciences has successfully completed an End-of-Phase 2 meeting with the FDA, confirming the design for a Phase 3 trial of canvuparatide for chronic hypoparathyroidism, set to begin in Q3 2026 [2][3] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders [2][8] - The company utilizes its proprietary Precision Endocrine Peptide™ (PEP™) platform technology to create novel therapies [6][8] Product Development - Canvuparatide is a parathyroid hormone peptide prodrug designed for once-weekly administration, aiming to restore physiologic PTH activity and maintain normocalcemia [6][7] - The Phase 3 trial will enroll approximately 160 patients, with a 3:1 randomization to receive canvuparatide or placebo, including a fixed dose period, dose-titration, and maintenance period [4][3] Market Potential - Chronic hypoparathyroidism affects over 250,000 individuals in the U.S. and Europe, with current treatments not addressing the underlying PTH deficiency [7] - Canvuparatide has received orphan drug designation from both the FDA and the European Medicines Agency, supporting its clinical development [5][6]

Core Insights - MBX Biosciences is on track to initiate Phase 3 trials for canvuparatide in Q3 2026 after a successful End-of-Phase 2 meeting with the FDA [1][2] - Canvuparatide aims to establish a new standard of care for chronic hypoparathyroidism by providing a once-weekly dosing regimen that restores physiologic PTH activity [2] - The Phase 3 trial will enroll approximately 160 patients and will include a double-blind placebo-controlled design [3] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders [1][7] - The company utilizes its proprietary Precision Endocrine Peptide™ (PEP™) platform technology to develop novel therapies [5][7] - The pipeline includes canvuparatide for chronic hypoparathyroidism, an obesity portfolio, and imapextide for post-bariatric hypoglycemia [8] Product Details - Canvuparatide is a parathyroid hormone peptide prodrug designed for long-acting hormone replacement therapy [5] - It has received orphan drug designation from both the FDA and the European Medicines Agency for the treatment of chronic hypoparathyroidism [4][5] - The treatment aims to provide continuous PTH exposure with lower daily peak-to-trough ratios compared to daily PTH dosing regimens [5] Disease Context - Chronic hypoparathyroidism is a rare endocrine disease affecting over 250,000 individuals in the U.S. and Europe, characterized by low calcium levels due to PTH deficiency [6] - Current treatments primarily involve high doses of oral calcium and active vitamin D supplements, which do not address the underlying PTH deficiency [6]

Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders [1][3] - The company will participate in two upcoming investor conferences, providing opportunities for engagement with investors [2] Company Overview - MBX Biosciences specializes in the discovery, development, and commercialization of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development [3] - The obesity portfolio includes MBX 4291 in Phase 1 development and several discovery and pre-clinical candidates [3] - Imapextide (MBX 1416) is in Phase 2 development for post-bariatric hypoglycemia [3] - The company is based in Carmel, Indiana [3]

Core Insights - MBX Biosciences, Inc. has appointed Laurie Stelzer as an independent director and chairperson of the audit committee, bringing extensive executive and financial leadership experience [1][2] - The company is focused on developing precision peptide therapies for endocrine and metabolic disorders, with a strong pipeline and a catalyst-rich year ahead [2][3] Company Overview - MBX Biosciences specializes in the discovery, development, and commercialization of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, an obesity portfolio with MBX 4291 in Phase 1, and imapextide (MBX 1416) for post-bariatric hypoglycemia in Phase 2 [3] Leadership and Governance - Laurie Stelzer has over 25 years of experience in finance and leadership roles across various biopharmaceutical companies, including previous positions as CFO at multiple firms [2] - Stelzer's expertise is expected to enhance the company's governance and strategic direction as it progresses through clinical trials [2]

Company Overview - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies for endocrine and metabolic disorders [3] - The company is based in Carmel, Indiana and utilizes its proprietary PEP™ platform for drug discovery [3] Pipeline Development - MBX Biosciences is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development [3] - The obesity portfolio includes MBX 4291, currently in Phase 1 development, along with multiple discovery and pre-clinical candidates [3] - Imapextide (MBX 1416) is in Phase 2 development for post-bariatric hypoglycemia [3] Upcoming Events - Kent Hawryluk, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026 [1] - The company presentation is scheduled for January 13, 2026, at 3:45 p.m. PT/6:45 p.m. ET [2] - A live webcast of the presentation will be available on the MBX Biosciences website, with a replay accessible for approximately 90 days [2]

Core Insights - MPM BioImpact has divested its entire stake in MBX Biosciences, selling 1,294,416 shares and reducing its exposure by approximately $14.8 million [2][7] - Despite the divestment by MPM, MBX Biosciences has shown strong performance, with its stock price increasing by 71% over the past year, significantly outperforming the S&P 500 [3][4] Company Overview - MBX Biosciences focuses on developing precision peptide therapies for endocrine and metabolic disorders, with key candidates including MBX 2109, MBX 1416, and MBX 4291 [5] - The company operates as a clinical-stage biopharmaceutical entity, aiming to generate value through research, development, and potential commercialization of its drug candidates [5] - As of the latest market close, MBX's stock price is $33.82, with a market capitalization of $1.5 billion and a net income of -$80.5 million over the trailing twelve months [4] Recent Developments - MBX reported positive topline Phase 2 results for canvuparatide in hypoparathyroidism and completed a $200 million upsized offering, ending the quarter with $391.7 million in cash, sufficient to fund operations into 2029 [9] - The CEO emphasized the potential of canvuparatide in a multibillion-dollar market and highlighted upcoming Phase 3 trials and key milestones expected in 2026 [9] - The stock has rebounded sharply after a significant decline post-IPO, reflecting a changed risk profile due to strengthening clinical data and renewed investor interest [6]

Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders [1][3] - The company will present at the 37th Annual Piper Sandler Healthcare Conference on December 2-4, 2025 [1][2] Company Overview - MBX Biosciences utilizes its proprietary PEP™ platform to discover and develop novel peptide therapies [3] - The company has a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism and imapextide (1416) for post-bariatric hypoglycemia, both in Phase 2 development [3] - An obesity portfolio is also in development, including MBX 4291 in Phase 1 and several pre-clinical candidates [3] - The company is based in Carmel, Indiana [3]

Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders [4] Upcoming Investor Conferences - The company will participate in several investor conferences, including: - Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, 2025, in Boston, MA [2] - Stifel Healthcare Conference on November 12, 2025, in New York, NY [2] - Jefferies Global Healthcare Conference on November 19, 2025, in London, UK [2] - TD Cowen Treatment Advancements in Obesity and Related Disorders Summit on November 24, 2025, virtually [3] Company Pipeline - MBX Biosciences is advancing a pipeline that includes: - Canvuparatide (MBX 2109) for chronic hypoparathyroidism, preparing for Phase 3 development [4] - Imapextide (1416) for post-bariatric hypoglycemia, currently in Phase 2 development [4] - An obesity portfolio including MBX 4291 in Phase 1 development and multiple discovery and pre-clinical candidates [4]

Core Insights - MBX Biosciences, Inc. is set to announce topline results from its Phase 2 clinical trial of canvuparatide for chronic hypoparathyroidism on September 22, 2025 [1] - The company will host a conference call and webcast to discuss the trial results, accessible via a live link or by phone [2] - MBX Biosciences focuses on developing precision peptide therapies for endocrine and metabolic disorders using its proprietary PEP™ platform [3] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for endocrine and metabolic disorders [3] - The company is advancing a pipeline of candidates targeting significant unmet medical needs with large market opportunities [3]